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Edited by Beat ImhofAbstract Anandamide (AEA) exhibits anti-inﬂammatory ef-
fects. However, its role in the periodontal ﬁeld remains unknown.
Here, we found that gingival crevicular ﬂuid contained a detect-
able level of AEA. The cannabinoid receptors CB1 and CB2
were expressed by human gingival ﬁbroblasts (HGFs), and
markedly upregulated under pathological conditions. AEA sig-
niﬁcantly reduced the production of pro-inﬂammatory mediators
(IL-6, IL-8 and MCP-1) induced by Porphyromonas gingivalis
LPS in HGFs, and this eﬀect was attenuated by AM251 and
SR144528, selective antagonists of CB1 and CB2, respectively.
Moreover, AEA completely blocked LPS-triggered NF-jB acti-
vation, implying that AEA may regulate hyperinﬂammatory
reactions in periodontitis.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Periodontitis is a major chronic inﬂammatory disease, that
destroys the periodontal tissue and eventually causes loss of
teeth. One of the main bacterial pathogen of human chronic
periodontitis is Porphyromonas gingivalis (Pg), which is a
gram-negative anaerobic bacterium. The bacterium expresses
a number of potential virulence factors including lipopolysac-
charide (LPS). LPS has been shown to stimulate host immune
cells to produce pro-inﬂammatory molecules via CD14 protein
and TLR4 expressed on the target membranes [1]. These pro-
inﬂammatory molecules are believed to induce several cellular
reactions, which eventually lead to an inﬂammatory status of
the periodontal tissue. At the same time, however, protectiveAbbreviations: AEA, N-arachidonoyl ethanolamine; HGFs, human
gingival ﬁbroblasts; Pg, Porphyromonas gingivalis; GCF, gingival
crevicular ﬂuid; PMB, polymyxin B; HPLC, high-performance liquid
chromatography; GAPDH, glyceraldehyde-3-phosphate dehydroge-
nase; EMSA, electrophoretic mobility shift assay
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doi:10.1016/j.febslet.2005.12.079mechanisms aimed at preventing a pathological outcome of
the pro-inﬂammatory insults are also induced. Hence, the
overall balance between the pro- and anti-inﬂammatory mech-
anisms is likely to determine the progression and severity of
periodontitis. However, the anti-inﬂammatory mechanism of
periodontal diseases remains to be explored.
Endocannabinoids are an emerging class of lipid mediators
derived from arachidonic acids and found in several tissues.
Anandamide, chemically deﬁned as N-arachidonoyl ethanol-
amine (AEA), and 2-arachidonoylglicerol (2-AG) are the main
endocannabinoid described to date [2], and can be generated
by activated macrophages via CD14 following exposure to
LPS [3]. Recently, endogenous and synthetic cannabinoids
have been reported to exhibit immunosuppressive and anti-
inﬂammatory eﬀects [4].
Therefore, we hypothesized that the LPS of periodonto-
pathic bacteria would stimulate host cells to release the endog-
enous cannabinoid AEA in periodontal tissues, which in turn
may reduce the excessive production of pro-inﬂammatory mol-
ecules through the activation of its CB1 and/or CB2 receptors.
The aims of the present study were to examine the levels of
AEA in gingival crevicular ﬂuid (GCF) and the expressions of
its CB1 and CB2 receptors in gingival ﬁbroblasts and to eval-
uate the possible role of AEA in periodontitis.2. Materials and methods
2.1. Reagents
LPS was extracted from lyophilized cells of Pg with phenol–water at
67 C for 20 min. The pooled extract in the water phase was dialyzed
against distilled water and ultracentrifuged at 140000 · g for 3 h to
separate LPS. The LPS sediment was resuspended in water and ultra-
centrifuged twice more by the previous method [5]. AEA and AM251,
a CB1-speciﬁc antagonist, were purchased from Calbiochem Novabio-
chem Co. (La Jolla, CA). Aﬃ-Prep polymyxin matrix was purchased
from Bio-Rad Laboratories (Hercules, CA). 3-(4,5-Dimethyl-2-thiaz-
olyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) was purchased
from Dojindo (Kumamoto, Japan). Phenylmethylsulfonyl ﬂuoride
(PMSF) was purchased from Wako Pure Chemicals Inc. Ltd. (Osaka,
Japan). Protease inhibitors (complete cocktail) were purchased from
Boehringer Mannheim (Germany). Goat polyclonal antibodies against
the CB1(sc-10066) and CB2(sc-10071) receptors were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). All other chemicals were
purchased from Sigma Chemical Co. (St. Louis, MO). SR144528, a
CB2-speciﬁc antagonist, was a kind gift from Sanoﬁ Recherche (Mont-
pellier, France).blished by Elsevier B.V. All rights reserved.
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Periodontitis, gingivitis and healthy periodontium were diagnosed as
previously described [6]. Brieﬂy, periodontitis exhibited a probing
pocket depth of 4–10 mm, alveolar bone loss, and bleeding on probing.
Gingivitis exhibited a probing pocket depth of less than 4 mm, no alve-
olar bone loss, and bleeding on probing. Healthy periodontium exhib-
ited a probing pocket depth less than 4 mm, with no alveolar bone loss
or bleeding on probing. Informed consent was obtained from the sub-
jects before resection of the gingival tissues.
2.3. GCF sampling
GCF was collected using periopaper (Proﬂow Inc., Amityville, NY)
as previously described [7]. Brieﬂy, periopaper was inserted into the
periodontal pocket for 30 s. After removing the paper from the site,
the GCF volume was recorded with a Periotron 8000 (Proﬂow Inc.)
and the paper was transferred to 1 ml of saline. Following an interval
of 60 s, the procedure was repeated twice.
2.4. AEA measurement by HPLC analysis
Taking advantage of the ability of polymyxin B (PMB) to bind to
AEA [8], we measured the levels of AEA in biological ﬂuids after selec-
tive absorption onto PMB-immobilized beads. The eluate from the
beads was directly fractionated using reverse-phase high-performance
liquid chromatography (HPLC). The fractions corresponding to
authentic AEA were collected, derivatized with a ﬂuorogenic reagent
and quantiﬁed by HPLC with ﬂuorometric detection as described
previously [9].
2.5. Cell culture for HGFs
Human gingival ﬁbroblasts (HGFs) were obtained from healthy and
inﬂamed gingival tissues according to a previously described method
[10]. Tissue samples were cultured in Dulbecco’s modiﬁed Eagle’s med-
ium (DMEM; Sigma) supplemented with 10% fetal bovine serum
(FBS), 100 U/ml of penicillin and 125 lg/ml of streptomycin at 37 C
in a humidiﬁed atmosphere of 95% air and 5% CO2. Cells growing
out from the tissues were subcultured and used for later experiments.
2.6. Immunohistochemistry
The expressions of CB1 and CB2 in inﬂamed human gingival tissues
were examined by immunohistochemistry using the labeled streptavi-
din biotin (LSAB) technique according to the manufacturer’s instruc-
tion. Brieﬂy, the inﬂamed gingival tissues were sectioned and stained
with antibodies against the CB1(1:80 dilution) and CB2(1:80 dilution)
receptors overnight at 4 C. Normal goat IgG was used as a negative
control. Next, the sections were incubated with a biotinylated anti-goat
antibody followed by incubation with peroxidase-conjugated streptavi-
din (LSAB Kit Peroxidase; DakoCytomation). The antibody localiza-
tion was determined using 3,3 0-diaminobenzidine (DAB) as the
substrate and counterstained with hematoxylin.2.7. RT-PCR
HGFs obtained from gingival tissues with diﬀerent disease statuses
(1 · 106 cells/ml) were seeded onto 100 mm cell culture dishes in
DMEM supplemented with 10% FBS with or without 100 ng/ml LPS
for the indicated times. Total RNA was extracted with TRIzol reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instruc-
tions. The puriﬁed total RNA (2 lg) was converted to cDNA by re-
verse transcriptase (RT; Gibco BRL, Gaithersburg, MD) and
ampliﬁed by RT-PCR. The ampliﬁcation proﬁle consisted of an initial
denaturation of 1 min at 94 C, followed by 35 cycles of 1 min at 94 C,
2 min at 62 C and 2 min at 72 C, and a ﬁnal extension of 5 min at
72 C. The following primers (purchased from Kurabo Industries
Ltd., Osaka, Japan) were used: CB1 sense: 5 0-CGTGGGCAGCC-
TGTTCCTCA-3 0; CB1 antisense: 5 0-CATGCGGGCTTGGTCTGG-
3 0; CB2 sense: 5 0-CGCCGGAAGCCCTCATACC-3 0; and CB2 anti-
sense: 5 0- CCTCATTCGGGCCATTCCTG-3 0. The glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as a housekeeping gene.2.8. Immunoblot analysis
HGFs obtained from gingival tissues with diﬀerent disease statuses
(1 · 106 cells/ml) were seeded onto 100 mm cell culture dishes in
DMEM supplemented with 10% FBS with or without 100 ng/mlLPS, and analyzed for their expressions of the CB1 and CB2 receptors
as described previously [11]. Brieﬂy, at the end of the culture, whole-
cell lysates were prepared by washing the cells with ice-cold PBS and
lysing them in sample buﬀer (62.5 mM Tris–HCl, pH 6.8, 2% SDS,
10% glycerol, 50 mM DTT, 1 mM PMSF, 0.5 mM Na2VO3 and prote-
ase inhibitors). Proteins were separated by 12% SDS–PAGE and trans-
ferred to a nitrocellulose membrane. The membrane was blocked with
5% non-fat milk and 1% bovine serum albumin for 1 h at room tem-
perature and then sequentially probed with an appropriate primary
antibody and horseradish peroxidase-conjugated secondary antibody.
The membranes were washed with Tris-buﬀered saline containing
0.1% Tween-20 and developed with a Western blotting ECL kit (Amer-
sham Biosciences, Buckinghamshire, UK).2.9. Evaluation of cell viability
Healthy HGFs were seeded at a density of 2–3 · 104 cells/well in 96-
well dishes and treated with AEA (20 lM) for 24 h. Next, the cell via-
bility was examined using an MTT assay as previously described [12].2.10. ELISA
Healthy HGFs (1 · 104 cells) were cultured in DMEM containing
1% FBS in the absence or presence of the indicated concentrations
of AEA for 2 h and then exposed to LPS (100 ng/ml) for 24 h. In some
experiments, HGFs were pre-incubated with AM251 (1 lM) or
SR144528 (1 lM) for 1 h and then incubated with or without AEA
for 2 h before further stimulation with LPS (100 ng/ml) for 24 h. At
the end of the treatment, the levels of IL-6, IL-8 and MCP-1 in the cul-
ture media were examined using appropriate ELISA Kits (Biosource,
Camarillo, CA) in triplicate. The minimum detectable doses of IL-6,
IL-8 and MCP-1 were less than 2, 5 and 20 pg/ml, respectively.
2.11. Electrophoretic mobility shift assay
Healthy HGFs were treated with 10 lMAEA in DMEM containing
1% FBS for 2 h prior to incubation with or without 100 ng/ml of LPS
for 2 h. Next, nuclear extracts were prepared and subjected to electro-
phoretic mobility shift assay (EMSA) as described previously [13].
Brieﬂy, double-stranded deoxyoligonucleotides containing the NF-jB
consensus recognition site (5 0-AGTTGAGGGGACTTTCCCAGGC-
3 0) were labeled with [c32]ATP using T4 polynucleotide kinase (Pro-
mega, Madison, WI). Next, a 10 lg sample of each nuclear extract
was incubated with 0.2 mg poly(dI-dC)/ml in a binding buﬀer (5 mM
MgCl2, 2.5 mM EDTA, 2.5 mM DTT, 250 mM NaCl, 50 mM Tris–
HCl, pH 7.5, 20% glycerol) for 20 min at room temperature after the
addition of a labeled probe. The mixtures were then electrophoresed,
and the gel was dried and exposed to X-ray ﬁlm at 80 C.
2.12. Statistical analysis
The data were presented as means ± S.D. and analyzed statistically
using Student’s t tests. Diﬀerences were considered signiﬁcant at
P < 0.01.3. Results and discussion
3.1. Detection of AEA in human GCF
The roles of endogenous cannabinoids in the pathogenesis of
various diseases in diﬀerent organs have been studied over re-
cent years. Some of the studies have indicated that these endo-
cannabinoids have anti-inﬂammatory properties [4].
In the current study, we investigated whether or not human
GCF contains AEA for the ﬁrst time. As shown in Table 1,
there was a detectable level of AEA in human GCF and its
concentration and amount were 4.63 ± 2.82 lg/ml and
16.4 ± 9.30 ng, from pathologic condition, respectively. Since
there was little collectable GCF from healthy condition, we
could not conclude these AEA concentration was pathologic
or not. There are two possible sources of the AEA in GCF.
Speciﬁcally, AEA may exude from the blood and/or arise
through local release from periodontal tissues as a result of
Table 1
AEA detection in human gingival crevicular ﬂuid
Poket
depth
(mm)
Clinical
atouch
level (mm)
Amount
of GCF
(ll)
Concentration
of AEA
(lg/ml)
Amount
of AEA
(ng)
7.33 ± 1.56 4.86 ± 3.29 4.00 ± 2.24 4.63 ± 2.82 16.4 ± 9.30
n = 12. Data are the means ± S.D.
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have shown that stimulation with bacterial LPS increases the
production of AEA and 2-AG by immune cells, including
macrophages [3].Fig. 1. Immunohistochemical detection of CB1 and CB2 expressions in inﬂa
tissues were incubated with biotinylated goat antibodies against CB1 and CB2
substrate for color development. (A) CB1; (B) CB2; (C) normal goat IgG. A
Fig. 2. RT-PCR analysis of CB1 and CB2 mRNA expressions in HGFs. Tot
periodontitis sites (A) or healthy HGFs exposed to Pg LPS (100 ng/ml) for 2
PCR using primers speciﬁc for CB1 and CB2. A photograph of the ethidium b
24 h; lane 3: LPS, 48 h. The results are representative of 3 independent expe3.2. Periodontal tissues express CB1 and CB2 receptors
Next, we investigated the expressions of cannabinoid recep-
tors in periodontal tissues by immunohistochemistry. As
shown in Fig. 1, both CB1 and CB2 were expressed in a num-
ber of ﬁbroblasts, endothelial cells and macrophage like cells in
the gingival connective tissue whereas no expression of CB1
and CB2 was observed in the negative control in which normal
goat IgG was used instead of primary antibodies against CB1
and CB2 (Fig. 1C), indicating the speciﬁcity of antibodies for
CB1 and CB2. Although endothelial cells and macrophages
have previously been reported to express CB1 and CB2
receptors [14,15], to the best of our knowledge there have no
reports to date on cannabinoid receptor expression in gingivalmed periodontal connective tissues. Sections of periodontal connective
, and then with peroxidase-conjugated streptavidin. DAB was used as a
rrows: HGFs; arrowheads: endothelial cells.
al RNA was isolated from HGFs obtained from healthy, gingivitis and
4 and 48 h (B). The mRNAs were reverse-transcribed and ampliﬁed by
romide-stained amplicons is shown. Lane 1: control, 48 h; lane 2: LPS,
riments. GAPDH was used as a control gene.
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that gingival ﬁbroblasts express CB1 and CB2 receptors.
Moreover, we were interested to note that some, but not all,
of the ﬁbroblasts were positive for CB1 and CB2 receptors.
Therefore, we next investigated whether or not the expressions
of CB1 and CB2 were correlated with the inﬂammatory status
of clinically diagnosed gingival tissues. For this purpose, the
expressions of CB1 and CB2 in HGFs obtained from various
stages of periodontal disease as well as from healthy volunteers
were evaluated by RT-PCR (Fig. 2A) and immunoblotting
analysis (Fig. 3A).
CB1 mRNA expression was detectable in all types of HGFs,
but signiﬁcantly higher in HGFs from gingivitis and periodon-
titis patients (Fig. 2A). On the other hand, CB2 mRNA wasFig. 3. Immunoblot analysis of CB1 and CB2 protein expressions in HGFs.
healthy HGFs exposed to Pg LPS (100 ng/ml) for 48 h (B) were analyzed
antibodies against CB1 and CB2. Lane 1: control, 48 h; lane 2: LPS, 48 h. T
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(Fig. 2A). Consistent with these RT-PCR results, Western blot
analysis also revealed signiﬁcant upregulation of CB1 and CB2
receptors in HGFs from gingivitis and periodontitis patients
(Fig. 3A). We further examined whether LPS treatment af-
fected the expression patterns of CB1 and CB2 receptors. As
shown in Figs. 2B and 3B, healthy HGFs exposed to Pg LPS
showed marked upregulation of CB1 and CB2 mRNAs at
24 h as determined by RT-PCR analysis and signiﬁcant upreg-
ulation of the corresponding proteins at 48 h as revealed by
immunoblot analysis. Several lines of evidence have indicated
that the activation of immune cells in response to LPS or other
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tory results indicating downregulation of these receptors
[18,19]. The discrepancies among these results may be due to
diﬀerences in the cell types or stimuli examined.
3.3. AEA reduces the production of pro-inﬂammatory mediators
induced by LPS in HGFs
AEA has been shown to inhibit the production of inﬂamma-
tory cytokines in mouse macrophage cultures [20] and cortical
astrocytes [21]. Recently, many functional roles of cannabinoid
receptors have been demonstrated, such as the regulation of
immune responses [4]. We investigated whether or not AEA af-
fects LPS-induced cytokine/chemokine production in HGFs.
As shown in Fig. 4, AEA dose-dependently reduced LPS-
induced production of IL-6, IL-8 and MCP-1 in HGFs. More-
over, the eﬀect of AEA was attenuated by pretreatment with
potent and selective antagonists of the cannabinoid CB1 and
CB2 receptors, namely AM251 (1 lM) and SR144528
(1 lM), respectively (Fig. 5), indicating the involvement of
cannabinoid receptors in mediating the AEA-induced anti-
inﬂammatory eﬀects in HGFs. These results are consistent
with recent reports demonstrating that cannabinoids inhibit
atherosclerosis, which is a chronic inﬂammatory disease, by
acting through CB2 receptors [22]. It has also been reported
that activation of CB1 and the endogenous cannabinoid sys-0
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24 h. At the end of the treatment, the levels of IL-6 (A), IL-8 (B) and MCP-1
the means ± S.D. of 3 experiments. *P < 0.01.tem is an early and important physiological step during self-
protection of the colon against inﬂammation [17]. Since
AEA has been reported to aﬀect cell viability in several cell
types [12], we next examined whether the suppressed release
of pro-inﬂammatory mediators by AEA was accompanied by
loss of HGF cell viability. Cell viability, as evaluated by
MTT assays, was unaﬀected by treatment with AEA up to
20 lM for 24 h (data not shown). Therefore, AEA-induced
cytotoxicity may depend on the degree of receptor expression,
cell type and fatty acid amide hydrolase (FAAH) enzyme (an
AEA-hydrolyzing enzyme) status, etc.
3.4. AEA blocks LPS-induced NF-jB activation
It is now well documented that the transcription factor NF-
jB plays a central role in most inﬂammatory processes by aug-
menting the expression of inﬂammatory genes, including those
for cytokines and chemokines. The results presented above
showed that 10 lM AEA signiﬁcantly reduced LPS-induced
production of IL-6, IL-8 and MCP-1. Therefore, we next inves-
tigated the eﬀect of AEA on LPS-induced NF-jB activation in
HGFs. We observed that AEA (10 lM) almost completely
blocked LPS-induced NF-jB activation (Fig. 6), indicating that
AEA suppressed pro-inﬂammatory mediators through block-
ing NF-jB activation. These results are supported by a previous
report that AEA inhibits NF-jB activation [23]. Furthermore,0
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Fig. 6. AEA inhibits the NF-jB activation induced by LPS in HGFs.
HGFs were pretreated with AEA (10 lM) for 2 h and then incubated
with or without 100 ng/ml Pg LPS for 2 h. After harvesting of the cells,
nuclear extracts were prepared and analyzed by EMSAs. Note that
AEA completely inhibits the NF-jB activation. The result shown is
representative of 3 independent experiments.
618 Y. Nakajima et al. / FEBS Letters 580 (2006) 613–619cannabinoids were reported to inhibit NF-jB activation and
reduce the upregulation of the NF-jB target genes TNFa and
IL-6 [24].
In conclusion, the present results demonstrate that AEA and
its receptors, CB1 and CB2, are present in periodontal tissues,
and indicate that these cannabinoid systems may be physiolog-
ically involved in protecting these tissues against excessive
inﬂammation by regulating cellular pathways leading to
inﬂammatory responses. Further studies are needed to exam-
ine the roles of endogenous cannabinoid systems in periodon-
tal diseases in more detail. Investigating the analgesic roles of
endogenous cannabinoid systems is also an issue for future re-
search. Such studies may lead to the development of novel
periodontal therapies and strategies for public oral health.
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